Drug discovery coup as Cresset acquires German company

Cresset provides innovative solutions for the digitisation of drug discovery and Molab.ai is a pioneer in artificial intelligence technologies tailored for molecular research.

The strategic acquisition will combine Cresset’s computational chemistry platform with Molab.ai’s proven capability to build highly predictive ADME models. It marks a significant step in Cresset’s mission to empower scientists with cutting-edge tools to accelerate drug discovery.

Molab.ai’s AI-driven software has been successfully applied in real-world projects to improve molecular property prediction, lead optimisation and virtual screening. Its integration into the Cresset ecosystem will offer researchers a unified platform for rapid and accurate prediction of biological activity and ADME properties, further advancing the digitisation of molecule discovery.

“We’re thrilled to welcome the Molab.ai team to the Cresset family,” said Tim Cheeseright, CEO of Cresset.

“Their pioneering work in AI aligns with our vision of delivering transformative technologies that improve the efficiency and success of drug discovery workflows.”

The acquisition reflects Cresset’s sustained investment in AI as part of a broad range of approaches to transform the impact of computation on early-stage discovery, accelerating the path from molecule to medicine. It also signals a commitment to investing in emerging technologies that complement the company’s core strengths in physics-based simulation and prediction.

Molab.ai will continue to operate from its current location, with plans to integrate its team and technologies into Cresset’s established AI team and broader R & D initiatives over the coming months.